Cardiovascular deterioration in STZ-diabetic rats: Possible role of vascular RAS

Pharmacology

Volumn 68, Issue 1, 2003, Pages 1-8

  Crespo, María J ^a   Moreta, Sovietsky ^a   González, Juan ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Cardiac output; Systolic blood pressure; Vascular angiotensin converting enzyme activity; Vascular function

Indexed keywords

ACETYLCHOLINE; DIPEPTIDYL CARBOXYPEPTIDASE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DETERIORATION; ENZYME ACTIVITY; HEART MUSCLE RELAXATION; HEART OUTPUT; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; THERMODILUTION; TISSUE HOMOGENATE;

ACETYLCHOLINE; ANIMALS; AORTA, ABDOMINAL; BLOOD PRESSURE; CARDIAC OUTPUT; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; MALE; MUSCLE, SMOOTH, VASCULAR; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; VASODILATOR AGENTS;

EID: 0037230550     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068725     Document Type: Article

References (44)

1. Garcia MJ, McNamara PM, Gordon I, Kannel WB: Morbidity and mortality in diabetics in the Framingham population: Sixteen years follow-up study. Diabetes 1994;23:104-111.
2. Neri S, Bruno CM, Leotta C, D'Amico RA, Pennisi G, Ierna D: Early endothelial alterations in non-insulin-dependent diabetes mellitus. Int J Clin Lab Res 1998;28:100-103.
3. Hsueh WA: Effect of the renin-angiotensin system in the vascular disease of type II diabetes mellitus. Am J Med 1992;92(suppl 4B):13-19.
4. Weidmann P, Berretta P, Calli C, Keusch G, Oluck Z, Mujagic M, Grinn M, Meier A, Zeig-ler WH: Sodium-volume factor, cardiovascular reactivity and hypotensive mechanisms of diuretic therapy in mild hypertension associated with diabetes mellitus. Am J Med 1979;67:779-784.
5. Shiffrin EL: The endothelium and control of blood vessel function in health and disease. Clin Invest Med 1994;17:602-620.
6. Cohen RA: The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis 1995;38: 105-128.
7. Ganda OP: Pathogenesis of macrovascular disease in the human diabetic. Diabetes 1980;29:931-942.
8. Berry K, Skyrme-Jones RA, Cameron JD, O'Brien RC, Meredith IT: Systemic arterial compliance is reduced in young patients with IDDM. Am J Physiol 1999;276:H1839-H1845.
9. Clarkson P, Celermajer DS, Donald AE, Sampson M, Sorensen KE, Adams M, Yue DK, Betteridge DJ, Deanfield JE: Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996;28:573-579.
10. Durante W, Sen AK, Sunahara FA: Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. Br J Pharmacol 1988;94:463-468.
11. Pieper GM: Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: Importance of disease duration. Diabetologia 1999;42:204-213.
12. Miranda FJ, Alabadi JA, Llorens S, Ruiz de Apodaca RF, Centeno JM, Alborch E: Influence of experimental diabetes on regulatory mechanisms of vascular response of rabbit carotid artery to acetylcholine. Life Sci 2000;66:2071-2080.
13. Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000;77:93-98.
14. Anderson S: Role of local and systemic angio-tensin in diabetic renal disease. Kidney Int Suppl 1997;63:107-110.
15. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993;265:F477-F486.
16. Cushman DW, Cheung HS: Concentrations of angiotensin converting enzyme activity in tissues of the rat. Biochim Biophys Acta 1991;250:261-265.
17. Sleight P: The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000;1:18-20.
18. Jandeleit K, Rumble J, Jackson B, Cooper ME: Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitus. Clin Exp Pharmacol Physiol 1992;19: 343-347.
19. Cooper ME, Rumble J, Komers R, Du HC, Jandeleit K, Chou ST: Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 1994;43:1221-1228.
20. Vranes D, Cooper ME, Dilley RJ: Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: Morphometric studies. J Vasc Res 1995;32:183-189.
21. Crespo MJ: Vascular alterations during the development and progression of experimental heart failure. J Card Fail 1999;5:55-63.
22. Crespo MJ, De Mello WC: Chronic administration of losartan plus hydrochlorothiazide improves vascular status in young cardiomyopathic hamsters. Eur J Pharmacol 2001;420:133-141.
23. Dzau VJ, Pratt R, Gibbons GH: Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease. Drugs 1994;47(suppl 4):1-13.
24. Schunkert H, Sadoshima J, Cornelius T, Kagaya Y, Weinberg EO, Izumo S, Riegger G, Lorell BH: Angiotensin II-induced growth responses in isolated adult rat hearts: Evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 1995;76:489-497.
25. Dostal DE, Baker KM: The cardiac renin-angiotensin system: Conceptual, or a regulator of cardiac function? Circ Res 1999;85:643-650.
26. De Mello WC, Crespo MJ: Cardiac refractoriness in rats is reduced by angiotensin II. J Cardiovasc Pharmacol 1995;25:51-56.
27. Ohnaka K, Numaguchi K, Yamakawa T, Inagami T: Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension 2000;35:68-75.
28. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW: Angiotensin II signaling in vascular smooth muscle: New concepts. Hypertension 1997;29:366-373.
29. Komers R, Oyama TT, Chapman JG, Allison KM, Anderson S: Effects of systemic inhibition of neuronal nitric oxide synthase in diabetic rats. Hypertension 2000;35:655-661.
30. Utkan T, Sarioglu Y, Yildirim S: Impaired contraction and relaxation in the aorta of streptozotocin-diabetic rats. Pharmacology 1998;56:207-215.
31. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA: Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510-2516.
32. Ustundag B, Cay M, Naziroglu M, Dilsiz N, Crabbe MJ, Ilhan N: The study of renin-angiotensin-aldosterone in experimental diabetes mellitus. Cell Biochem Funct 2001;17:193-198.
33. Kennefick TM, Anderson S: Role of angioten-sin II in diabetic nephropathy. Semin Nephrol 1997;17:441-447.
34. Pohl U, de Wit C: A unique role of NO in the control of blood flow. News Physiol Sci 1999;14:74-80.
35. Arnal JF, Battle T, Rasetti C, Challah M, Cos-terousse O, Vicaut E, Michel JB, Alhenc-Gelas F: ACE in three tunicae of rat aorta: Expression in smooth muscle and effect of renovascular hypertension. Am J Physiol 1994;267:H1777-H1784.
36. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH: Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990;39:1116-1124.
37. Giannattasio C, Failla M, Grappiolo A, Gamba PL, Paleari F, Mancia G: Progression of large artery structural and functional alterations in type I diabetes. Diabetologia 2001;44:203-208.
38. Brands MW, Fitzgerald SM: Acute endothelium-mediated vasodilation is not impaired at the onset of diabetes. Hypertension 1998;32:541-547.
39. Claxton CR, Brands MW, Fitzgerald SM, Cameron JA: Inhibition of nitric oxide synthesis potentiates hypertension during chronic glucose infusion in rats. Hypertension 2000;35:451-456.
40. Brodsky SV, Morrishow AM, Dharia N, Gross S, Goligorsky MS: Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol 2001;280:F480-F486.
41. Brands MW, Fitzgerald SM: Blood pressure control early in diabetes: A balance between angiotensin II and nitric oxide. Clin Exp Pharmacol Physiol 2002;29:127-131.
42. Brands MW, Fitzgerald SM: Arterial pressure control at the onset of type I diabetes: The role of nitric oxide and the renin-angiotensin system. Am J Hypertens 2001;14(suppl):126-131.
43. Brands MW, Fitzgerald SM, Hewitt WH, Hailman AE: Decreased cardiac output at the onset of diabetes: Renal mechanisms and peripheral vasoconstriction. Am J Physiol Endocrinol Metab 2000;278:E917-E924.
44. Bakris GL: Angiotensin-converting enzyme inhibitors and the progression of diabetic nephropathy. Ann Intern Med 1993;118:643-644.